Perdagangan Lineage Cell Therapeutics, Inc. - LCTX CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.025457% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | 0.003235% | ||||||||
Waktu biaya inap | 21:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Lineage Cell Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.31 |
Open* | 1.32 |
1-Year Change* | -10.81% |
Day's Range* | 1.25 - 1.33 |
52 wk Range | 1.02-1.79 |
Average Volume (10 days) | 413.10K |
Average Volume (3 months) | 7.57M |
Market Cap | 229.74M |
P/E Ratio | -100.00K |
Shares Outstanding | 170.17M |
Revenue | 11.85M |
EPS | -0.14 |
Dividend (Yield %) | N/A |
Beta | 1.69 |
Next Earnings Date | Aug 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 7, 2023 | 1.31 | -0.03 | -2.24% | 1.34 | 1.35 | 1.31 |
Jun 6, 2023 | 1.32 | 0.06 | 4.76% | 1.26 | 1.36 | 1.26 |
Jun 5, 2023 | 1.25 | -0.01 | -0.79% | 1.26 | 1.29 | 1.22 |
Jun 2, 2023 | 1.29 | 0.04 | 3.20% | 1.25 | 1.31 | 1.24 |
Jun 1, 2023 | 1.25 | 0.02 | 1.63% | 1.23 | 1.27 | 1.22 |
May 31, 2023 | 1.24 | 0.03 | 2.48% | 1.21 | 1.27 | 1.21 |
May 30, 2023 | 1.22 | -0.06 | -4.69% | 1.28 | 1.28 | 1.22 |
May 26, 2023 | 1.26 | 0.01 | 0.80% | 1.25 | 1.27 | 1.25 |
May 25, 2023 | 1.25 | -0.02 | -1.57% | 1.27 | 1.29 | 1.25 |
May 24, 2023 | 1.29 | 0.01 | 0.78% | 1.28 | 1.32 | 1.28 |
May 23, 2023 | 1.29 | -0.04 | -3.01% | 1.33 | 1.35 | 1.29 |
May 22, 2023 | 1.32 | -0.03 | -2.22% | 1.35 | 1.36 | 1.32 |
May 19, 2023 | 1.33 | 0.01 | 0.76% | 1.32 | 1.36 | 1.32 |
May 18, 2023 | 1.31 | -0.02 | -1.50% | 1.33 | 1.36 | 1.31 |
May 17, 2023 | 1.34 | 0.00 | 0.00% | 1.34 | 1.36 | 1.34 |
May 16, 2023 | 1.32 | 0.00 | 0.00% | 1.32 | 1.36 | 1.31 |
May 15, 2023 | 1.36 | 0.03 | 2.26% | 1.33 | 1.37 | 1.32 |
May 12, 2023 | 1.35 | -0.04 | -2.88% | 1.39 | 1.41 | 1.35 |
May 11, 2023 | 1.39 | 0.00 | 0.00% | 1.39 | 1.41 | 1.37 |
May 10, 2023 | 1.40 | -0.02 | -1.41% | 1.42 | 1.46 | 1.39 |
Lineage Cell Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, August 9, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q2 2023 Lineage Cell Therapeutics Inc Earnings Release Q2 2023 Lineage Cell Therapeutics Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 8, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Lineage Cell Therapeutics Inc Earnings Release Q3 2023 Lineage Cell Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 14.703 | 4.341 | 1.826 | 3.515 | 4.988 |
Revenue | 14.703 | 4.341 | 1.826 | 3.515 | 4.988 |
Cost of Revenue, Total | 0.728 | 1.426 | 0.385 | 0.412 | 0.302 |
Gross Profit | 13.975 | 2.915 | 1.441 | 3.103 | 4.686 |
Total Operating Expense | 37.223 | 53.029 | 28.273 | 42.391 | -31.728 |
Selling/General/Admin. Expenses, Total | 22.508 | 18.212 | 15.571 | 24.031 | 24.726 |
Research & Development | 13.887 | 33.714 | 11.117 | 15.948 | 18.755 |
Unusual Expense (Income) | 0 | -0.523 | 0 | -77.711 | |
Operating Income | -22.52 | -48.688 | -26.447 | -38.876 | 36.716 |
Interest Income (Expense), Net Non-Operating | -1.365 | 3.727 | 1.817 | 16.499 | -82.531 |
Other, Net | -1.927 | 1.691 | 2.706 | 3.143 | -1.315 |
Net Income Before Taxes | -25.812 | -43.27 | -21.924 | -19.234 | -47.13 |
Net Income After Taxes | -26.353 | -43.27 | -20.685 | -11.827 | -46.784 |
Minority Interest | 0.08 | 0.251 | 0.036 | 0.118 | 0.794 |
Net Income Before Extra. Items | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Net Income | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Income Available to Common Incl. Extra. Items | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Dilution Adjustment | |||||
Diluted Net Income | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Diluted Weighted Average Shares | 169.792 | 164.502 | 150.044 | 145.533 | 126.903 |
Diluted EPS Excluding Extraordinary Items | -0.15474 | -0.26151 | -0.13762 | -0.08046 | -0.3624 |
Diluted Normalized EPS | -0.15474 | -0.26469 | -0.13762 | -0.08046 | -0.75823 |
Depreciation / Amortization | 0.1 | 0.2 | 1.2 | 2 | 2.2 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 2.386 | 1.915 | 2.998 | 4.553 | 5.237 |
Revenue | 2.386 | 1.915 | 2.998 | 4.553 | 5.237 |
Cost of Revenue, Total | 0.119 | 0.102 | 0.235 | 0.215 | 0.176 |
Gross Profit | 2.267 | 1.813 | 2.763 | 4.338 | 5.061 |
Total Operating Expense | 9.028 | 8.554 | 8.249 | 8.787 | 11.633 |
Selling/General/Admin. Expenses, Total | 4.724 | 4.348 | 4.422 | 5.27 | 8.469 |
Research & Development | 4.185 | 4.104 | 3.592 | 3.302 | 2.988 |
Depreciation / Amortization | |||||
Operating Income | -6.642 | -6.639 | -5.251 | -4.234 | -6.396 |
Interest Income (Expense), Net Non-Operating | 0.45 | -0.123 | 0.151 | -0.658 | -0.734 |
Other, Net | -0.015 | 0.4 | -0.475 | -1.89 | 0.037 |
Net Income Before Taxes | -6.207 | -6.362 | -5.575 | -6.782 | -7.093 |
Net Income After Taxes | -4.404 | -6.362 | -6.116 | -6.782 | -7.093 |
Minority Interest | 0.032 | 0.008 | 0.047 | 0.019 | 0.006 |
Net Income Before Extra. Items | -4.372 | -6.354 | -6.069 | -6.763 | -7.087 |
Net Income | -4.372 | -6.354 | -6.069 | -6.763 | -7.087 |
Income Available to Common Excl. Extra. Items | -4.372 | -6.354 | -6.069 | -6.763 | -7.087 |
Income Available to Common Incl. Extra. Items | -4.372 | -6.354 | -6.069 | -6.763 | -7.087 |
Diluted Net Income | -4.372 | -6.354 | -6.069 | -6.763 | -7.087 |
Diluted Weighted Average Shares | 170.127 | 170.002 | 169.786 | 169.731 | 169.647 |
Diluted EPS Excluding Extraordinary Items | -0.0257 | -0.03738 | -0.03574 | -0.03985 | -0.04177 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.0257 | -0.03738 | -0.03574 | -0.03985 | -0.04177 |
Unusual Expense (Income) | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 60 | 111.549 | 43.999 | 57.519 | 36.358 |
Cash and Short Term Investments | 57.875 | 58.358 | 41.562 | 30.716 | 30.741 |
Cash & Equivalents | 11.355 | 55.742 | 32.585 | 9.497 | 23.587 |
Short Term Investments | 46.52 | 2.616 | 8.977 | 21.219 | 7.154 |
Total Receivables, Net | 0.297 | 50.84 | 0.004 | 23.94 | 3.719 |
Accounts Receivable - Trade, Net | 0.297 | 50.84 | 0.004 | 0.044 | 0.891 |
Prepaid Expenses | 1.828 | 2.351 | 2.433 | 2.863 | 1.898 |
Total Assets | 123.664 | 174.545 | 107.949 | 125.478 | 101.66 |
Property/Plant/Equipment, Total - Net | 5.673 | 4.872 | 5.63 | 8.175 | 5.835 |
Property/Plant/Equipment, Total - Gross | 11.523 | 10.174 | 9.945 | 12.766 | 9.02 |
Accumulated Depreciation, Total | -5.85 | -5.302 | -4.315 | -4.591 | -3.185 |
Intangibles, Net | 46.692 | 46.822 | 47.032 | 48.248 | 3.125 |
Long Term Investments | 0 | 33.733 | |||
Other Long Term Assets, Total | 0.627 | 0.63 | 0.616 | 0.864 | 0.505 |
Total Current Liabilities | 18.981 | 47.116 | 7.769 | 6.494 | 6.812 |
Accounts Payable | 2.393 | 3.543 | 2.611 | 2.427 | 2.359 |
Accrued Expenses | 7.131 | 25.049 | 4.416 | 3.985 | 4.332 |
Notes Payable/Short Term Debt | 0 | 0 | 0.523 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.036 | 0.03 | 0.016 | 0.033 | 0.07 |
Other Current Liabilities, Total | 9.421 | 18.494 | 0.203 | 0.049 | 0.051 |
Total Liabilities | 50.325 | 82.324 | 11.75 | 12.519 | 7.82 |
Total Long Term Debt | 0.084 | 0.03 | 0.026 | 0.077 | 1.958 |
Long Term Debt | 0 | ||||
Capital Lease Obligations | 0.084 | 0.03 | 0.026 | 0.077 | 1.958 |
Minority Interest | -1.403 | -1.323 | -1.072 | -1.712 | -1.594 |
Other Liabilities, Total | 30.587 | 34.425 | 2.951 | 4.345 | 0.644 |
Total Equity | 73.339 | 92.221 | 96.199 | 112.959 | 93.84 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 440.28 | 434.529 | 393.944 | 387.062 | 354.27 |
Retained Earnings (Accumulated Deficit) | -363.37 | -337.097 | -294.078 | -273.422 | -261.856 |
Treasury Stock - Common | |||||
Other Equity, Total | -3.571 | -5.211 | -3.667 | -0.681 | 1.426 |
Total Liabilities & Shareholders’ Equity | 123.664 | 174.545 | 107.949 | 125.478 | 101.66 |
Total Common Shares Outstanding | 170.093 | 169.477 | 153.096 | 149.804 | 127.136 |
Note Receivable - Long Term | 0 | 22.104 | |||
Goodwill, Net | 10.672 | 10.672 | 10.672 | 10.672 | |
Deferred Income Tax | 2.076 | 2.076 | 2.076 | 3.315 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 49.655 | 60 | 68.509 | 74.026 | 81.872 |
Cash and Short Term Investments | 46.814 | 57.875 | 66.355 | 72.03 | 79.944 |
Cash & Equivalents | 15.451 | 11.355 | 24.752 | 70.857 | 78.062 |
Short Term Investments | 31.363 | 46.52 | 41.603 | 1.173 | 1.882 |
Total Receivables, Net | 0.203 | 0.297 | 0.434 | 0.707 | 0.515 |
Accounts Receivable - Trade, Net | 0.203 | 0.297 | 0.434 | 0.707 | 0.515 |
Prepaid Expenses | 2.638 | 1.828 | 1.72 | 1.289 | 1.413 |
Total Assets | 113.205 | 123.664 | 131.148 | 135.922 | 144.52 |
Property/Plant/Equipment, Total - Net | 5.584 | 5.673 | 4.652 | 3.869 | 4.548 |
Property/Plant/Equipment, Total - Gross | 11.694 | 11.523 | 10.464 | 9.414 | 10.135 |
Accumulated Depreciation, Total | -6.11 | -5.85 | -5.812 | -5.545 | -5.587 |
Goodwill, Net | 10.672 | 10.672 | 10.672 | 10.672 | 10.672 |
Intangibles, Net | 46.659 | 46.692 | 46.724 | 46.757 | 46.789 |
Other Long Term Assets, Total | 0.635 | 0.627 | 0.591 | 0.598 | 0.639 |
Total Current Liabilities | 17.225 | 18.981 | 22.739 | 25.091 | 24.593 |
Accounts Payable | 3.001 | 2.393 | 2.865 | 2.589 | 2.956 |
Accrued Expenses | 3.126 | 7.131 | 7.46 | 6.678 | 6.642 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.051 | 0.036 | 0.025 | 0.029 | 0.031 |
Other Current Liabilities, Total | 11.047 | 9.421 | 12.389 | 15.795 | 14.964 |
Total Liabilities | 42.755 | 50.325 | 52.2 | 53.075 | 57.973 |
Total Long Term Debt | 0.133 | 0.084 | 0.016 | 0.019 | 0.026 |
Capital Lease Obligations | 0.133 | 0.084 | 0.016 | 0.019 | 0.026 |
Deferred Income Tax | 0.273 | 2.076 | 2.076 | 2.076 | 2.076 |
Minority Interest | -1.435 | -1.403 | -1.395 | -1.348 | -1.329 |
Other Liabilities, Total | 26.559 | 30.587 | 28.764 | 27.237 | 32.607 |
Total Equity | 70.45 | 73.339 | 78.948 | 82.847 | 86.547 |
Common Stock | 441.299 | 440.28 | 439.148 | 437.151 | 435.818 |
Retained Earnings (Accumulated Deficit) | -367.742 | -363.37 | -357.016 | -350.947 | -344.184 |
Other Equity, Total | -3.107 | -3.571 | -3.184 | -3.357 | -5.087 |
Total Liabilities & Shareholders’ Equity | 113.205 | 123.664 | 131.148 | 135.922 | 144.52 |
Total Common Shares Outstanding | 170.174 | 170.093 | 169.886 | 169.748 | 169.727 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -26.273 | -43.019 | -20.649 | -11.709 | -45.99 |
Cash From Operating Activities | 1.059 | -23.561 | -19.753 | -31.947 | -30.882 |
Cash From Operating Activities | 0.582 | 0.663 | 0.895 | 1.131 | 1.081 |
Amortization | 0.145 | 0.21 | 1.216 | 1.998 | 2.192 |
Deferred Taxes | |||||
Non-Cash Items | 7.901 | -2.511 | -2.516 | -21.464 | 11.197 |
Cash Interest Paid | 0.013 | 0.013 | 0.02 | 0.028 | 0.155 |
Changes in Working Capital | 18.704 | 21.096 | 1.301 | -1.903 | 0.638 |
Cash From Investing Activities | -46.159 | 9.745 | 13.038 | 16.957 | 11.816 |
Capital Expenditures | -0.413 | -0.354 | -0.064 | -0.44 | -3.287 |
Other Investing Cash Flow Items, Total | -45.746 | 10.099 | 13.102 | 17.397 | 15.103 |
Cash From Financing Activities | 1.632 | 36.93 | 29.865 | 0.617 | 5.774 |
Financing Cash Flow Items | -0.123 | -1.155 | -0.383 | 0.654 | 0.161 |
Issuance (Retirement) of Stock, Net | 1.787 | 38.105 | 5.127 | 0.063 | 5.962 |
Issuance (Retirement) of Debt, Net | -0.032 | -0.02 | 25.121 | -0.1 | -0.349 |
Foreign Exchange Effects | -0.873 | -0.02 | -0.063 | 0.07 | 0.006 |
Net Change in Cash | -44.341 | 23.094 | 23.087 | -14.303 | -13.286 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.372 | -26.273 | -19.919 | -13.85 | -7.087 |
Cash From Operating Activities | -11.242 | 1.059 | 9.362 | 14.842 | 21.904 |
Cash From Operating Activities | 0.138 | 0.582 | 0.441 | 0.296 | 0.15 |
Amortization | 0.033 | 0.145 | 0.113 | 0.065 | 0.032 |
Non-Cash Items | 1.098 | 7.901 | 7.168 | 5.861 | 1.685 |
Cash Interest Paid | 0.002 | 0.013 | 0.013 | 0.009 | 0.005 |
Changes in Working Capital | -8.139 | 18.704 | 21.559 | 22.47 | 27.124 |
Cash From Investing Activities | 15.426 | -46.159 | -41.057 | -0.143 | -0.046 |
Capital Expenditures | -0.188 | -0.413 | -0.429 | -0.143 | -0.046 |
Other Investing Cash Flow Items, Total | 15.614 | -45.746 | -40.628 | 0 | 0 |
Cash From Financing Activities | 0.001 | 1.632 | 1.51 | 0.546 | 0.513 |
Financing Cash Flow Items | -0.037 | -0.123 | -0.112 | -0.074 | -0.008 |
Issuance (Retirement) of Stock, Net | 0.051 | 1.787 | 1.645 | 0.635 | 0.529 |
Foreign Exchange Effects | -0.1 | -0.873 | -0.795 | -0.161 | -0.042 |
Net Change in Cash | 4.085 | -44.341 | -30.98 | 15.084 | 22.329 |
Deferred Taxes | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | -0.013 | -0.032 | -0.023 | -0.015 | -0.008 |
Cash Taxes Paid | 1.803 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Broadwood Capital, Inc. | Hedge Fund | 20.5293 | 34935485 | 0 | 2023-04-17 | LOW |
Kingsley (Alfred D) | Individual Investor | 4.0249 | 6849242 | 0 | 2023-04-17 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8225 | 6504938 | 397884 | 2023-03-31 | LOW |
Defender Capital LLC | Investment Advisor | 3.0181 | 5136085 | 42550 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.1625 | 3679968 | -74234 | 2023-03-31 | LOW |
Laurion Capital Management LP | Hedge Fund | 1.3974 | 2377940 | 0 | 2023-03-31 | HIGH |
Prescott General Partners LLC | Hedge Fund | 1.0882 | 1851851 | 0 | 2023-03-31 | LOW |
Raffles Capital Management, LLC | Hedge Fund | 0.9032 | 1536946 | 0 | 2023-03-31 | LOW |
BofA Global Research (US) | Research Firm | 0.8484 | 1443779 | 1442750 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 0.8239 | 1402123 | 1003084 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7533 | 1282000 | 17591 | 2023-03-31 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.5644 | 960512 | 0 | 2023-03-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.4797 | 816387 | 642768 | 2023-03-31 | HIGH |
Bridgeway Capital Management, LLC | Investment Advisor | 0.4594 | 781766 | 0 | 2023-03-31 | |
Jane Street Capital, L.L.C. | Research Firm | 0.3505 | 596444 | 455199 | 2023-03-31 | HIGH |
Citi Investment Research (US) | Research Firm | 0.272 | 462884 | -14290 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2571 | 437496 | 0 | 2023-03-31 | LOW |
MAI Capital Management, LLC | Investment Advisor/Hedge Fund | 0.2498 | 425115 | -31702 | 2023-03-31 | LOW |
ETF Managers Group, LLC | Investment Advisor | 0.1872 | 318596 | -35395 | 2023-03-31 | MED |
Morgan Stanley & Co. LLC | Research Firm | 0.1703 | 289882 | 169284 | 2023-03-31 | MED |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group535K+
Trader
87K+
Klien aktif per bulan
$113M+
Volume investasi per bulan
$64M+
Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Industry: | Biotechnology & Medical Research (NEC) |
2173 Salk Ave Ste 200
CARLSBAD
CALIFORNIA 92008-7354
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 535.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com